Drug
Istiratumab clinical trials
Also written MM-141.
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2012
How studies write it
Studies that test it under each name
Development codes
- MM-141
- 3
Studies by the year they started
3 studies that test it; most in 2015 (2)
| Year | Studies |
|---|---|
| 2012 | 1 |
| 2015 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 3 · Other 0
Often tested with
Tested in the same studies.
Gemcitabine (1) · Albumin-Bound Paclitaxel (1) · Paclitaxel (1) · Seribantumab (1) · Trametinib (1)
Studies
Open first, then newest update. How each study uses Istiratumab is read from its arms, and is right about nine times in ten.
Testing it · 3
- A Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic CancerCompletedPhase 2Merrimack PharmaceuticalsNCT02399137Written as MM-141
- Phase 1 Combination Study of MM-151 With MM-121, MM-141, or TrametinibTerminatedPhase 1Merrimack PharmaceuticalsNCT02538627Written as MM-141
- A Phase 1 Study of MM-141 in Patients With Advanced Solid TumorsCompletedPhase 1Merrimack PharmaceuticalsNCT01733004Written as MM-141
Codes
What other systems call Istiratumab · ClinicalTrials.gg INT000167
- MeSH (NLM) C000595155IstiratumabOne source NLM
- UNII (FDA) XLR461MD3MISTIRATUMABConfirmed FDA, NLM, Wikidata
- Wikidata Q30314127istiratumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C103863IstiratumabOne source FDA
- DrugBank DB15363One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000595155 | Istiratumab | One source NLM |
| UNII (FDA) | XLR461MD3M | ISTIRATUMAB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q30314127 | istiratumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C103863 | Istiratumab | One source FDA |
| DrugBank | DB15363 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.